- Achieve Life Sciences Inc (NASDAQ:ACHV) has announced positive topline results from the Phase 3 ORCA-2 trial of 3mg cytisinicline for 6-weeks or 12-weeks compared to a placebo in 810 adult smokers.
- The 6- and 12-week cytisinicline treatments demonstrated significantly better quit rates than placebo, with odds ratios of 8.0 and 6.3, respectively.
- Subjects who received 12 weeks of cytisinicline treatment had a 6.3 times higher likelihood of quitting smoking during the last 4 weeks of treatment than subjects who received placebo.
- The abstinence rate during weeks 9-12 was 32.6% for cytisinicline compared to 7.0% for placebo.
- Subjects who received 6 weeks of cytisinicline treatment had an 8 times higher likelihood of quitting smoking, with an abstinence rate of 25.3% compared to 4.4% for placebo.
- The continuous abstinence rate from week 9 to 24 was 21.1% for the 12-week cytisinicline arm compared to 4.8% for placebo, with an odds ratio of 5.3.
- The continuous abstinence rate from week 3 to 24 was 8.9% for the 6-week cytisinicline arm compared to 2.6% for placebo, with an odds ratio of 3.7.
- Cytisinicline was well tolerated, with no treatment-related serious adverse events reported.
- After the data, Achieve Life Sciences can withdraw the remaining $10 million under the $25 million debt facility from Silicon Valley Bank.
- Price Action: ACHV shares are down 6.52% at $6.45 during the market session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks